Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)

Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficientl...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Diego Orsini, Giacomo Caldarola, Annunziata Dattola, Elena Campione, Nicoletta Bernardini, Pasquale Frascione, Clara De Simone, Antonio G. Richetta, Marco Galluzzo, Nevena Skroza, Chiara Assorgi, Emanuele Amore, Gennaro M. Falco, Ruslana Gaeta Shumak, Fabio Artosi, Giulia Maretti, Concetta Potenza, Luca Bianchi, Giovanni Pellacani, Ketty Peris, Claudio Bonifati, Dario Graceffa
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2024-12-01
coleção:	Journal of Dermatological Treatment
Assuntos:	Tildrakizumab immunomodulatory therapies biologics psoriasis psoriasis treatment anti-IL-23-biologics
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2319304
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!